


Now available

to order on the Federal
Supply Schedule!

omnipod
5
automated insulin
delivery system



THE FIRST AND ONLY

tubeless, automated insulin
delivery system cleared for
type 1 and type 2 diabetes



SIMPLIFIED COST.



No high up-front costs

Unlike other insulin pumps for which the pump and ongoing supplies are billed, Omnipod 5 does not have a pump component cost



No sunk costs

Avoid unrecoverable cost of a pump to your agency's budget if your patient stops using Omnipod 5



Pharmacy pay-as-you-go pricing

Provides predictable monthly budgeting, as costs only include Omnipod 5 ongoing supplies

IT'S SIMPLE FOR YOU.

Omnipod® 5 is always adjusting so you don't have to.

RECEIVE

real-time data at your fingertips through automatic uploads.

PROVIDES

customizable targets between 110-150 mg/dL, adjustable by time of day in increments of 10 mg/dL.

HELPS PROTECT

against hypoglycemia by decreasing or pausing insulin delivery if lows are predicted or experienced.^{1,2}

ADJUSTS

insulin delivery automatically, adapting to changing insulin needs with every new Pod.

HELPS CORRECT

high glucose values every 5 minutes with microboluses based on current glucose levels and a 60-minute prediction.^{1,2}

Pod shown without the necessary adhesive.

References: **1.** Brown S. et al. *Diabetes Care*. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, $P<0.0001$; 7.67% vs 6.99%, $P<0.0001$, respectively. Mean time 70-180 mg/dL as measured by CGM in adults/adolescents and children, ST vs. Omnipod 5: 64.7% vs. 73.9%, $P<0.0001$; 52.5% vs. 68.0%, $P<0.0001$, respectively. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, $P<0.0001$, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, $P<0.0001$; 1.4% vs. 1.5%, $P=0.8153$, respectively. Results measured by CGM. **2.** Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, $P<0.05$. Mean time in range (70-180mg/dL) in very young children (2 - 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, $P<0.05$. Mean time >180 mg/dL in very young children (2 - 5.9 yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, $P<0.0001$. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, $P=0.0185$. Results measured by CGM. **3.** USA 2023, Data on file.

IT'S SIMPLE FOR THEM.

—

**200-unit Pod reservoir,
up to 72-hour wear**

Tube-free, discreet

**Automatic cannula
insertion**

Waterproof*

**Flexibility in sensor
and smartphone
control of choice†**

*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.

†For a list of compatible smartphone devices, visit omnipod.com/compatibility.



IT'S SIMPLE TO ACCESS.

Now available to order on
the Federal Supply Schedule

Omnipod 5

NDC	Nomenclature	Contents	Sensor Compatibility
08508-3000-01	Omnipod 5 DexG7G6 Intro Kit (Gen 5)	Controller 10 Pods	Dexcom G7 Dexcom G6
08508-3000-75	Omnipod 5 DexG7G6 Pods (Gen 5)	5 Pods	Dexcom G7 Dexcom G6
08508-3000-88	Omnipod 5 Libre2Plus G6 Intro Kit (Gen 5)	Controller 10 Pods	FreeStyle Libre 2 Plus Dexcom G6
08508-3000-42	Omnipod 5 Libre2Plus G6 Pods (Gen 5)	5 Pods	FreeStyle Libre 2 Plus Dexcom G6

Omnipod DASH® Insulin Management System

NDC	Nomenclature	Contents	Sensor Compatibility
08508-2000-05	Omnipod DASH Pods (Gen 4)	5 Pods	N/A

LEARN MORE.



Visit www.omnipod.com/hcp/products/omnipod5

The Omnipod® 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.

Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.

© 2024 Insulet Corporation. Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Dexcom, Dexcom G6 and Dexcom G7 are registered trademarks of Dexcom, Inc. and used with permission. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott Diabetes Care Inc and used with permission in the United States various jurisdictions. The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. November 2024 INS-OHS-10-2024-00315 V2

Insulet Corporation • 100 Nagog Park, Acton, MA 01720 • 800-591-3455 • omnipod.com/hcp

omnipod
automated insulin
delivery system
5

